These results suggested that anti-CD47 mAb can efficiently trigger the phagocytosis of CD113+ cells by macrophages, indicating that anti-CD47 that anti-CD47 mAb can be used as a new therapeutic strategy for clinical cancer treatments in the future. Here, NECTIN3 is linked to cancer.